ADMA Biologics, Inc.
ADMA
$9.37
-$0.17-1.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 512.28M | 509.86M | 510.17M | 488.56M | 474.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 512.28M | 509.86M | 510.17M | 488.56M | 474.17M |
| Cost of Revenue | 180.81M | 197.45M | 217.41M | 221.28M | 222.86M |
| Gross Profit | 331.47M | 312.42M | 292.77M | 267.28M | 251.32M |
| SG&A Expenses | 103.25M | 98.86M | 96.42M | 96.37M | 92.91M |
| Depreciation & Amortization | 199.00K | 176.00K | 146.00K | 120.00K | 110.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 295.77M | 303.01M | 318.73M | 321.55M | 318.53M |
| Operating Income | 216.50M | 206.86M | 191.44M | 167.01M | 155.64M |
| Income Before Tax | 216.47M | 206.33M | 182.66M | 155.78M | 145.01M |
| Income Tax Expenses | 47.52M | 40.98M | 35.73M | -53.67M | -63.92M |
| Earnings from Continuing Operations | 168.96 | 165.35 | 146.93 | 209.45 | 208.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 168.96M | 165.35M | 146.93M | 209.45M | 208.93M |
| EBIT | 216.50M | 206.86M | 191.44M | 167.01M | 155.64M |
| EBITDA | 224.19M | 214.82M | 199.54M | 175.01M | 163.55M |
| EPS Basic | 0.72 | 0.69 | 0.62 | 0.88 | 0.88 |
| Normalized Basic EPS | 0.56 | 0.53 | 0.49 | 0.42 | 0.39 |
| EPS Diluted | 0.70 | 0.68 | 0.60 | 0.82 | 0.82 |
| Normalized Diluted EPS | 0.55 | 0.52 | 0.47 | 0.41 | 0.37 |
| Average Basic Shares Outstanding | 940.88M | 954.14M | 955.84M | 954.30M | 950.27M |
| Average Diluted Shares Outstanding | 958.81M | 977.08M | 981.80M | 983.85M | 983.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |